Antineoplastic Combined Chemotherapy Protocols

Publication Title: 
Oncotarget

To improve prognosis in recurrent glioblastoma we developed a treatment protocol based on a combination of drugs not traditionally thought of as cytotoxic chemotherapy agents but that have a robust history of being well-tolerated and are already marketed and used for other non-cancer indications.

Author(s): 
Kast, Richard E.
Boockvar, John A.
Brüning, Ansgar
Cappello, Francesco
Chang, Wen-Wei
Cvek, Boris
Dou, Q. Ping
Duenas-Gonzalez, Alfonso
Efferth, Thomas
Focosi, Daniele
Ghaffari, Seyed H.
Karpel-Massler, Georg
Ketola, Kirsi
Khoshnevisan, Alireza
Keizman, Daniel
Magné, Nicolas
Marosi, Christine
McDonald, Kerrie
Muñoz, Miguel
Paranjpe, Ameya
Pourgholami, Mohammad H.
Sardi, Iacopo
Sella, Avishay
Srivenugopal, Kalkunte S.
Tuccori, Marco
Wang, Weiguang
Wirtz, Christian R.
Halatsch, Marc-Eric
Publication Title: 
Oncotarget

CUSP9 treatment protocol for recurrent glioblastoma was published one year ago. We now present a slight modification, designated CUSP9*. CUSP9* drugs--aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, sertraline, ritonavir, are all widely approved by regulatory authorities, marketed for non-cancer indications. Each drug inhibits one or more important growth-enhancing pathways used by glioblastoma. By blocking survival paths, the aim is to render temozolomide, the current standard cytotoxic drug used in primary glioblastoma treatment, more effective.

Author(s): 
Kast, Richard E.
Karpel-Massler, Georg
Halatsch, Marc-Eric
Publication Title: 
Asian Pacific journal of cancer prevention: APJCP

BACKGROUND: Patients with colorectal cancer are usually treated with chemotherapy, which reduces the number of blood cells, especially white blood cells, and consequently increases the risk of infections. Some research studies have reported that aromatherapy massage affects the immune system and improves immune function by, for example, increasing the numbers of natural killer cells and peripheral blood lymphocytes.

Author(s): 
Khiewkhern, Santisith
Promthet, Supannee
Sukprasert, Aemkhea
Eunhpinitpong, Wichai
Bradshaw, Peter
Publication Title: 
Cancer Research

Berberine, an isoquinoline alkaloid derived from a plant used traditionally in Chinese and Ayurvedic medicine, has been reported to exhibit chemopreventive and anti-inflammatory activities through unknown mechanism. Because of the critical role of the transcription factor nuclear factor-kappaB (NF-kappaB) in these processes, we investigated the effect of berberine on this pathway. We found that berberine suppressed NF-kappaB activation induced by various inflammatory agents and carcinogens. This alkaloid also suppressed constitutive NF-kappaB activation found in certain tumor cells.

Author(s): 
Pandey, Manoj K.
Sung, Bokyung
Kunnumakkara, Ajaikumar B.
Sethi, Gautam
Chaturvedi, Madan M.
Aggarwal, Bharat B.
Publication Title: 
Cancer Research

Berberine, an isoquinoline alkaloid derived from a plant used traditionally in Chinese and Ayurvedic medicine, has been reported to exhibit chemopreventive and anti-inflammatory activities through unknown mechanism. Because of the critical role of the transcription factor nuclear factor-kappaB (NF-kappaB) in these processes, we investigated the effect of berberine on this pathway. We found that berberine suppressed NF-kappaB activation induced by various inflammatory agents and carcinogens. This alkaloid also suppressed constitutive NF-kappaB activation found in certain tumor cells.

Author(s): 
Pandey, Manoj K.
Sung, Bokyung
Kunnumakkara, Ajaikumar B.
Sethi, Gautam
Chaturvedi, Madan M.
Aggarwal, Bharat B.
Publication Title: 
Psycho-Oncology

BACKGROUND: Women under age 50, a quarter of all cases of breast cancer, are especially vulnerable to physical and psychosocial late effects of their treatment due to having more aggressive treatment and their relative youth. METHODS: In person interviews were conducted with the population-based sample: 185 women who were under 50 at diagnosis and were cancer-free 5 years later. Quality of life in the physical, psychological, social, and spiritual domains was assessed and compared with results obtained a few months after diagnosis.

Author(s): 
Bloom, Joan R.
Stewart, Susan L.
Chang, Subo
Banks, Priscilla J.
Publication Title: 
Psycho-Oncology

BACKGROUND: Women under age 50, a quarter of all cases of breast cancer, are especially vulnerable to physical and psychosocial late effects of their treatment due to having more aggressive treatment and their relative youth. METHODS: In person interviews were conducted with the population-based sample: 185 women who were under 50 at diagnosis and were cancer-free 5 years later. Quality of life in the physical, psychological, social, and spiritual domains was assessed and compared with results obtained a few months after diagnosis.

Author(s): 
Bloom, Joan R.
Stewart, Susan L.
Chang, Subo
Banks, Priscilla J.
Publication Title: 
Molecular Carcinogenesis

Although tamoxifen (TAM) is used for the front-line treatment and prevention of estrogen receptor-positive (ER+) breast tumors, nearly 40% of estrogen-dependent breast tumors do not respond to TAM treatment. Moreover, the positive response is usually of short duration, and most tumors eventually develop TAM-resistance. Overexpression of HER2 gene is associated with TAM-resistance of breast tumor, and suppression of HER2 expression enhances the TAM activity. Soy isoflavone genistein has been shown to have anti-cancer activities and suppress expression of HER2 and ERalpha.

Author(s): 
Mai, Zhiming
Blackburn, George L.
Zhou, Jin-Rong
Publication Title: 
Blood

Most anticancer chemotherapies are immunosuppressive and induce nonimmunogenic tumor cell death. Bortezomib, a specific inhibitor of 26S proteasome, has shown clinical activity in several human tumors, including myeloma. Here we show that the uptake of human myeloma cells by dendritic cells (DCs) after tumor cell death by bortezomib, but not gamma irradiation or steroids, leads to the induction of antitumor immunity, including against primary tumor cells, without the need for any additional adjuvants.

Author(s): 
Spisek, Radek
Charalambous, Anna
Mazumder, Amitabha
Vesole, David H.
Jagannath, Sundar
Dhodapkar, Madhav V.
Publication Title: 
Free Radical Biology & Medicine

The major tea polyphenol, (-)-epigallocatechin-3-gallate (EGCG), inhibits carcinogenesis in many in vivo models. Many potential mechanisms of action have been proposed based on cell line studies, including prooxidant activity. In the present study, we studied the effect of N-acetylcysteine (NAC) on the inhibitory effects of EGCG on lung cancer cell growth. We found that NAC (0-2 mM) dose dependently enhanced the growth inhibitory activity of EGCG against murine and human lung cancer cells.

Author(s): 
Lambert, Joshua D.
Sang, Shengmin
Yang, Chung S.

Pages

Subscribe to RSS - Antineoplastic Combined Chemotherapy Protocols